Aurinia Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Aurinia Pharmaceuticals's earnings have been declining at an average annual rate of -7.3%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 61% per year.
Key information
-7.3%
Earnings growth rate
1.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 61.0% |
| Return on equity | -20.6% |
| Net Margin | -44.5% |
| Next Earnings Update | 02 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Aurinia Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 176 | -78 | 195 | 42 |
| 30 Sep 23 | 159 | -77 | 192 | 2 |
| 30 Jun 23 | 160 | -73 | 197 | 0 |
| 31 Mar 23 | 147 | -97 | 201 | 0 |
| 31 Dec 22 | 134 | -108 | 196 | 42 |
| 30 Sep 22 | 129 | -115 | 194 | 32 |
| 30 Jun 22 | 88 | -157 | 186 | 0 |
| 31 Mar 22 | 66 | -168 | 179 | 0 |
| 31 Dec 21 | 46 | -181 | 174 | 47 |
| 30 Sep 21 | 72 | -156 | 168 | 0 |
| 30 Jun 21 | 58 | -148 | 154 | 0 |
| 31 Mar 21 | 51 | -127 | 125 | 0 |
| 31 Dec 20 | 50 | -103 | 97 | 0 |
| 30 Sep 20 | 0 | -129 | 64 | 0 |
| 30 Jun 20 | 0 | -110 | 40 | 0 |
| 31 Mar 20 | 0 | -102 | 29 | 0 |
| 31 Dec 19 | 0 | -88 | 22 | 0 |
| 30 Sep 19 | 0 | -57 | 19 | 0 |
| 30 Jun 19 | 0 | -52 | 15 | 0 |
| 31 Mar 19 | 0 | -61 | 14 | 0 |
| 31 Dec 18 | 0 | -53 | 14 | 0 |
| 30 Sep 18 | 0 | -53 | 14 | 0 |
| 30 Jun 18 | 0 | -48 | 14 | 0 |
| 31 Mar 18 | 0 | -34 | 13 | 0 |
| 31 Dec 17 | 0 | -71 | 12 | 0 |
| 30 Sep 17 | 0 | -76 | 11 | 0 |
| 30 Jun 17 | 0 | -70 | 10 | 0 |
| 31 Mar 17 | 0 | -71 | 9 | 0 |
| 31 Dec 16 | 0 | -23 | 7 | 0 |
| 30 Sep 16 | 0 | -19 | 6 | 0 |
| 30 Jun 16 | 0 | -17 | 6 | 0 |
| 31 Mar 16 | 0 | -14 | 6 | 0 |
| 31 Dec 15 | 0 | -19 | 6 | 0 |
| 30 Sep 15 | 0 | -21 | 6 | 0 |
| 30 Jun 15 | 0 | -13 | 6 | 0 |
| 31 Mar 15 | 0 | -23 | 6 | 0 |
| 31 Dec 14 | 0 | -19 | 7 | 0 |
| 30 Sep 14 | 1 | -15 | 6 | 0 |
| 30 Jun 14 | 1 | -17 | 5 | 0 |
| 31 Mar 14 | 1 | -7 | 4 | 0 |
| 31 Dec 13 | 1 | -3 | 2 | 0 |
| 30 Sep 13 | 0 | -6 | 2 | 0 |
| 30 Jun 13 | 0 | -8 | 3 | 0 |
Quality Earnings: IKAP is currently unprofitable.
Growing Profit Margin: IKAP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IKAP is unprofitable, and losses have increased over the past 5 years at a rate of 7.3% per year.
Accelerating Growth: Unable to compare IKAP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IKAP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: IKAP has a negative Return on Equity (-20.64%), as it is currently unprofitable.